Cagrilintide
Symbol Cg · MW 4409 Da
Long-acting amylin analog studied alongside semaglutide for weight loss.
- Discovered
- 2021
- Half-life
- 8 days
- Approval
- Investigational
Reported effects
- Appetite suppression
- Satiety
- Synergy with GLP-1s
Overview
Cagrilintide is a long-acting amylin analog peptide being studied for weight management, appetite control, and obesity treatment. Amylin is a hormone involved in satiety, blood sugar regulation, and slowing gastric emptying, which helps promote a feeling of fullness after eating. Cagrilintide is often discussed alongside GLP-1 weight loss medications because it may complement appetite-regulating pathways. Its main purpose is to reduce hunger, improve satiety, and support lower calorie intake over time. As a modern weight loss peptide, Cagrilintide represents a newer class of metabolic peptides focused on appetite regulation rather than stimulant-based fat burning.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- Investigational research range: 0.3–4.5 mg
- Typical Frequency
- Once weekly
Research sources
Source links included from peer-reviewed literature and trusted medical journal records for this peptide.
Interested in Cagrilintide?
Enter your email and we'll send you a curated list of vendors we trust for sourcing this peptide.
No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions.